| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 4 | +100.00% | +7.86% | +0.83% | +7.03% | +4.95% | — |
| 14d | 4 | +75.00% | +1.41% | +0.22% | +1.19% | +1.80% | — |
| 30d | 4 | +75.00% | +4.37% | +1.28% | +3.10% | +7.21% | — |
| 60d | 4 | +75.00% | +26.21% | +4.19% | +22.02% | +13.20% | — |
| 90d | 4 | +50.00% | +31.62% | +6.28% | +37.12% | +12.76% | — |
| 180d | 4(1 pending) | +66.67% | +11.14% | +10.53% | +0.61% | +9.83% | — |
| 1y | 4(1 pending) | +66.67% | +30.64% | +29.31% | +1.33% | +36.63% | — |
| 2y | 4(1 pending) | +66.67% | +90.24% | +43.88% | +46.36% | +96.94% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| NMTC NEUROONE MEDICAL TECHNOLOGIES CORP | PURCHASE Chief Business Officer | 1,000,000 | $0.67 | $670.4K | 1,000,000 | Mar 1, 2026 | Mar 3, 2026 ↗ | View → |
| NMTC NEUROONE MEDICAL TECHNOLOGIES CORP | PURCHASEGRANT Stock grant | 500,000 | — | — | 500,000 | Mar 1, 2026 | Mar 3, 2026 ↗ | View → |
| DMAC DIAMEDICA THERAPEUTICS INC. | PURCHASEGRANT Stock grant | 250,000 | — | — | 250,000 | Jun 1, 2025 | Jun 3, 2025 ↗ | View → |
| DMAC DIAMEDICA THERAPEUTICS INC. | PURCHASEGRANT Stock grant | 130,000 | — | — | 130,000 | Jun 1, 2024 | Jun 3, 2024 ↗ | View → |
| DMAC DIAMEDICA THERAPEUTICS INC. | PURCHASE Chief Business Officer | 20,000 | $2.46 | $49.2K | 527,114 | Nov 16, 2023 | Nov 16, 2023 ↗ | View → |
| DMAC DIAMEDICA THERAPEUTICS INC. | PURCHASE Chief Business Officer | 38,364 | $3.91 | $150.0K | 507,114 | Jun 23, 2023 | Jun 26, 2023 ↗ | View → |
| DMAC DIAMEDICA THERAPEUTICS INC. | PURCHASE Chief Business Officer | 468,750 | $1.60 | $750.0K | 468,750 | Apr 10, 2023 | Apr 11, 2023 ↗ | View → |
| DMAC DIAMEDICA THERAPEUTICS INC. | PURCHASEGRANT Stock grant | 140,000 | — | — | 140,000 | Apr 10, 2023 | Apr 11, 2023 ↗ | View → |